Polymer Factory to Terminate Liquidity Guarantee for Its Shares

Polymer Factory said it will terminate its liquidity guarantee agreement with Pareto Securities, with the final day of liquidity-providing trading set for January 20, 2026, a decision the company frames as part of an evaluation of its capital market activities to streamline administrative and operational processes. The dendritic-materials specialist — which supplies delivery systems to BigPharma, MedTech, Biotech and research institutions and markets a patented SpheriCal® calibration technology for mass spectrometry — said it will continue to monitor trading conditions and assess future needs for market-related support, a change investors should note given the withdrawal of formal liquidity provision.

Analysis

Polymer Factory has notified the market it will terminate its liquidity guarantee agreement with Pareto Securities, with the final day of guaranteed liquidity set for January 20, 2026, and the company saying the move is part of an evaluation of its capital market activities to streamline administrative and operational processes. The firm will continue to monitor trading conditions and assess future needs for market-related support, signaling that this is a strategic, administrative decision rather than a statement about core operations.

The withdrawal of a formal liquidity provider creates a realistic risk of wider bid-ask spreads, reduced order-book depth and greater intraday volatility, particularly for larger trades or in thin trading sessions; external sentiment indicators classify the news as mildly negative and the market-impact score is modest, implying limited immediate disruption but heightened caution. Institutional execution costs and price discovery could be affected until alternative arrangements or organic liquidity emerge, so trading conditions merit active monitoring.

Fundamentally, the company’s business—dendritic materials sold to BigPharma, MedTech, BioTech and research institutions and its patented SpheriCal® mass-spectrometry calibration technology—remains unchanged by the liquidity agreement decision, which suggests the decision is driven by capital markets administration and cost/operational considerations. Investors should treat this as a liquidity and governance event with potential short-to-medium-term market effects rather than a change to the company’s technological or commercial outlook.

Key Decisions for Investors

• Monitor daily trading volume, bid-ask spreads and order-book depth ahead of and after the January 20, 2026 termination and avoid initiating large positions until post-termination liquidity is observable
• Request clarity from management on contingency plans (alternative liquidity providers, buyback programs or staged support) since the company said it will assess future market-related needs
• If maintaining or initiating sizeable exposure, consider staging trades or using limit orders and hedges to control execution risk while valuation assessment remains focused on the company’s dendritic materials and SpheriCal® IP